Sign in →

TEST ID C2729 Breast Carcinoma-Associated Antigen, Serum

Reporting Name

Breast Carcinoma Assoc Ag(CA 27.29)

Specimen Type

Serum


Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions:

1. Within 2 hours of collection, centrifuge and aliquot serum into a plastic vial. Specimens that have not been aliquoted will be canceled.

2. Send refrigerated.


Specimen Minimum Volume

0.25 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  90 days
  Ambient  4 days

Method Name

Chemiluminometric Immunoassay

Reject Due To

Gross hemolysis Reject
Gross lipemia OK

Reference Values

Males

≥18 years: ≤38.0 U/mL (use not defined)

Females

≥18 years: ≤38.0 U/mL

Reference values have not been established for patients who are younger than 18 years of age.

Serum markers are not specific for malignancy, and values may vary by method.

Day(s) Performed

Monday through Friday

Report Available

Same day/1 to 3 days

Specimen Retention Time

3 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

86300

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-General Request (T239)

-Oncology Test Request (T729)

Useful For

Aiding in the management of breast cancer in patients with metastatic disease by monitoring the progression or regression of disease in response to treatment

 

Serial testing in women with prior stage II or III breast cancer who are clinically free of disease

 

May be useful for predicting early recurrence of disease in women with treated carcinoma of the breast

 

This test is not useful for screening women for or diagnosis of carcinoma of the breast.

Highlights

The US Food and Drug Administration has approved CA 27.29 for serial testing in women with prior stage II or III breast cancer who are clinically free of disease.